|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||108.06 - 109.98|
|52-week range||105.26 - 143.90|
|Beta (5Y monthly)||0.13|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||2.80 (2.59%)|
|Ex-dividend date||11 Aug 2022|
|1y target est||N/A|
In addition to favorable price action, all three carry a strong growth profile, making them appear even more enticing.
Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.